On the 14th day after the first dose of COVID-19 vaccine, 5.4% (5/93) of participants were positive for IgM antibodies in serum, 3.2% (3/93) were positive for IgG antibodies, and 24.7% (23/93) were positive for the surrogate NAb responses. This evidence concerns the gene CD40LG and COVID-19.